Lin Ding

Mr. Lin Ding

University of Technology Sydney, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
ARAlexey Rzhevskiy
Alexey Rzhevskiy
Sajad Razavi BazazSajad Razavi Bazaz
Sajad Razavi Bazaz
LDLin Ding
Lin Ding
AKAlina Kapitannikova
Alina Kapitannikova
Nima SayydiNima Sayydi
Nima Sayydi
Andrei ZvyaginAndrei Zvyagin
Andrei Zvyagin
During the last decade, isolation of circulating tumour cells via blood liquid biopsy of prostate cancer (PCa) has attracted significant attention as an alternative, or substitute, to conventional diagnostic tests. However, it was previously determined that localised forms of PCa shed a small number of cancer cells into the bloodstream, and a large volume of blood is required just for a single test, which is impractical. To address this issue, urine has been used as an alternative to blood for liquid biopsy as a truly non-invasive, patient-friendly test. To this end, we developed a spiral microfluidic chip capable of isolating PCa cells from the urine of PCa patients. Potential clinical utility of the chip was demonstrated using anti-Glypican-1 (GPC-1) antibody as a model of the primary antibody in immunofluorescent assay for identification and detection of the collected tumour cells. The microchannel device was first evaluated using DU-145 cells in a diluted Dulbecco’s phosphate-buffered saline sample, where it demonstrated >85 (±6) % efficiency. The microchannel proved to be functional in at least 79% of cases for capturing GPC1+ putative tumour cells from the urine of patients with localised PCa. More importantly, a correlation was found between the amount of the captured GPC1+ cells and crucial diagnostic and prognostic parameter of localised PCa—Gleason score. Thus, the technique demonstrated promise for further assessment of its diagnostic value in PCa detection, diagnosis, and prognosis.

13 September 2022 in Micromachines
Verified
Journal Article
Open access
PDF file
LDLin Ding
Lin Ding
Sajad Razavi BazazSajad Razavi Bazaz
Sajad Razavi Bazaz
JSJesus Shrestha
Jesus Shrestha
Hoseyn A. AmiriHoseyn A. Amiri
Hoseyn A. Amiri
SMSima Mas-hafi
Sima Mas-hafi
Majid Ebrahimi WarkianiMajid Ebrahimi Warkiani
Majid Ebrahimi Warkiani
Cryopreservation is the final step of stem cell production before the cryostorage of the product. Conventional methods of adding cryoprotecting agents (CPA) into the cells can be manual or automated with robotic arms. However, challenging issues with these methods at industrial-scale production are the insufficient mixing of cells and CPA, leading to damage of cells, discontinuous feeding, the batch-to-batch difference in products, and, occasionally, cross-contamination. Therefore, the current study proposes an alternative way to overcome the abovementioned challenges; a highly efficient micromixer for low-cost, continuous, labour-free, and automated mixing of stem cells with CPA solutions. Our results show that our micromixer provides a more homogenous mixing of cells and CPA compared to the manual mixing method, while the cell properties, including surface markers, differentiation potential, proliferation, morphology, and therapeutic potential, are well preserved.